EVALUATION OF CELLULAR IMMUNE RESPONSE DURING XENOVACCINE THERAPY OF THE PATIENTS WITH STAGE IV OF COLORECTAL CANCER

Abstract. Thirty-seven patients with stage colorectal cancer stage IV were subjected to immunotherapy using a polyantigenic vaccine, prepared, basically, from lyzed cells of murine melanoma (B16) and murine carcinoma (LLC) cells. The inducing course of xenovaccine therapy consisted of 10 subcutaneou...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	M. A. Felde, D. M. Samarin, N. A. Niza, A. A. Shishkov, O. V. Poveshenko, E. A. Kashchenko, V. I. Seledtsov, G. V. Seledtsova, V. A. Kozlov
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2014
Materias:	colorectal cancer xenovaccine cellular immunity Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/757558f0b1024b68b9dd005a9703770c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:757558f0b1024b68b9dd005a9703770c
record_format	dspace
spelling	oai:doaj.org-article:757558f0b1024b68b9dd005a9703770c2021-11-18T08:03:41ZEVALUATION OF CELLULAR IMMUNE RESPONSE DURING XENOVACCINE THERAPY OF THE PATIENTS WITH STAGE IV OF COLORECTAL CANCER1563-06252313-741X10.15789/1563-0625-2006-1-67-72https://doaj.org/article/757558f0b1024b68b9dd005a9703770c2014-07-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/433https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XAbstract. Thirty-seven patients with stage colorectal cancer stage IV were subjected to immunotherapy using a polyantigenic vaccine, prepared, basically, from lyzed cells of murine melanoma (B16) and murine carcinoma (LLC) cells. The inducing course of xenovaccine therapy consisted of 10 subcutaneous immunizations (5 injections weekly followed by 5 bi-weekly). Consolidating treatment included monthly vaccinations. Ther xenovaccine therapy was not associated with any serious adverse effects, and did not influence the composition of blood lymphocyte subsets. Significant increase in cellular immune reactions to vaccinal carcinoma-associated antigens occurred in the patients after an inducing treatment, as determined by both skin and antigen-driven blastogenesis test. The overall 2-year survival of thirty-seven stage IV colorectal cancer patients was shown to be significantly better, than in control group (37 clinically comparable patients), with median survival rates of 17 and 7 months, respectively.M. A. FeldeD. M. SamarinN. A. NizaA. A. ShishkovO. V. PoveshenkoE. A. KashchenkoV. I. SeledtsovG. V. SeledtsovaV. A. KozlovSPb RAACIarticlecolorectal cancerxenovaccinecellular immunityImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 8, Iss 1, Pp 67-72 (2014)
institution	DOAJ
collection	DOAJ
language	RU
topic	colorectal cancer xenovaccine cellular immunity Immunologic diseases. Allergy RC581-607
spellingShingle	colorectal cancer xenovaccine cellular immunity Immunologic diseases. Allergy RC581-607 M. A. Felde D. M. Samarin N. A. Niza A. A. Shishkov O. V. Poveshenko E. A. Kashchenko V. I. Seledtsov G. V. Seledtsova V. A. Kozlov EVALUATION OF CELLULAR IMMUNE RESPONSE DURING XENOVACCINE THERAPY OF THE PATIENTS WITH STAGE IV OF COLORECTAL CANCER
description	Abstract. Thirty-seven patients with stage colorectal cancer stage IV were subjected to immunotherapy using a polyantigenic vaccine, prepared, basically, from lyzed cells of murine melanoma (B16) and murine carcinoma (LLC) cells. The inducing course of xenovaccine therapy consisted of 10 subcutaneous immunizations (5 injections weekly followed by 5 bi-weekly). Consolidating treatment included monthly vaccinations. Ther xenovaccine therapy was not associated with any serious adverse effects, and did not influence the composition of blood lymphocyte subsets. Significant increase in cellular immune reactions to vaccinal carcinoma-associated antigens occurred in the patients after an inducing treatment, as determined by both skin and antigen-driven blastogenesis test. The overall 2-year survival of thirty-seven stage IV colorectal cancer patients was shown to be significantly better, than in control group (37 clinically comparable patients), with median survival rates of 17 and 7 months, respectively.
format	article
author	M. A. Felde D. M. Samarin N. A. Niza A. A. Shishkov O. V. Poveshenko E. A. Kashchenko V. I. Seledtsov G. V. Seledtsova V. A. Kozlov
author_facet	M. A. Felde D. M. Samarin N. A. Niza A. A. Shishkov O. V. Poveshenko E. A. Kashchenko V. I. Seledtsov G. V. Seledtsova V. A. Kozlov
author_sort	M. A. Felde
title	EVALUATION OF CELLULAR IMMUNE RESPONSE DURING XENOVACCINE THERAPY OF THE PATIENTS WITH STAGE IV OF COLORECTAL CANCER
title_short	EVALUATION OF CELLULAR IMMUNE RESPONSE DURING XENOVACCINE THERAPY OF THE PATIENTS WITH STAGE IV OF COLORECTAL CANCER
title_full	EVALUATION OF CELLULAR IMMUNE RESPONSE DURING XENOVACCINE THERAPY OF THE PATIENTS WITH STAGE IV OF COLORECTAL CANCER
title_fullStr	EVALUATION OF CELLULAR IMMUNE RESPONSE DURING XENOVACCINE THERAPY OF THE PATIENTS WITH STAGE IV OF COLORECTAL CANCER
title_full_unstemmed	EVALUATION OF CELLULAR IMMUNE RESPONSE DURING XENOVACCINE THERAPY OF THE PATIENTS WITH STAGE IV OF COLORECTAL CANCER
title_sort	evaluation of cellular immune response during xenovaccine therapy of the patients with stage iv of colorectal cancer
publisher	SPb RAACI
publishDate	2014
url	https://doaj.org/article/757558f0b1024b68b9dd005a9703770c
work_keys_str_mv	AT mafelde evaluationofcellularimmuneresponseduringxenovaccinetherapyofthepatientswithstageivofcolorectalcancer AT dmsamarin evaluationofcellularimmuneresponseduringxenovaccinetherapyofthepatientswithstageivofcolorectalcancer AT naniza evaluationofcellularimmuneresponseduringxenovaccinetherapyofthepatientswithstageivofcolorectalcancer AT aashishkov evaluationofcellularimmuneresponseduringxenovaccinetherapyofthepatientswithstageivofcolorectalcancer AT ovpoveshenko evaluationofcellularimmuneresponseduringxenovaccinetherapyofthepatientswithstageivofcolorectalcancer AT eakashchenko evaluationofcellularimmuneresponseduringxenovaccinetherapyofthepatientswithstageivofcolorectalcancer AT viseledtsov evaluationofcellularimmuneresponseduringxenovaccinetherapyofthepatientswithstageivofcolorectalcancer AT gvseledtsova evaluationofcellularimmuneresponseduringxenovaccinetherapyofthepatientswithstageivofcolorectalcancer AT vakozlov evaluationofcellularimmuneresponseduringxenovaccinetherapyofthepatientswithstageivofcolorectalcancer
_version_	1718422484505591808

EVALUATION OF CELLULAR IMMUNE RESPONSE DURING XENOVACCINE THERAPY OF THE PATIENTS WITH STAGE IV OF COLORECTAL CANCER

Ejemplares similares